Azacitidine‐associated haemorrhagic enteritis in a case of myelodysplastic syndrome: A case report

Autor:	Miki Umeda, Hisashi Tsutsumi, Wataru Shinomiya, Hiroko Hidai, Hideki Akiyama, Yoshiaki Shibata, Reina Saga, Takeshi Hagino, Sayuri Motomura, Miwa Kurimoto
Rok vydání:	2020
Předmět:	Pharmacology medicine.medical_specialty Intestinal ulcers business.industry Azacitidine Case description 030226 pharmacology & pharmacy Gastroenterology stomatognathic diseases 03 medical and health sciences 0302 clinical medicine Internal medicine medicine heterocyclic compounds Pharmacology (medical) 030212 general & internal medicine business Adverse effect neoplasms Haemorrhagic enteritis medicine.drug
Zdroj:	Journal of Clinical Pharmacy and Therapeutics. 45:828-831
ISSN:	1365-2710 0269-4727
DOI:	10.1111/jcpt.13146
Popis:	What is known and objective 5-Azacitidine (AZA) is an agent widely used to treat myelodysplastic syndrome (MDS). Case description We herein report an 83-year-old woman diagnosed with MDS who was treated with AZA. She tolerated the first cycle of AZA; however, severe adverse events involving haemorrhagic enteritis with multiple intestinal ulcers developed after the second and third cycles. Additionally, the interval between the administration of AZA and the development of haematochezia shortened with each cycle of AZA. What is new and conclusion We herein report as-yet-undescribed potential side effects, AZA-associated haemorrhagic enteritis that should be kept in mind.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::42ce0ecb9231a9246e29181c94ecfc9e https://doi.org/10.1111/jcpt.13146 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.